Written question asked by Lord Mendelsohn (Labour) on Wednesday, 15 March 2023, in the House of Lords. It was due for an answer on Wednesday, 29 March 2023. It was answered by Lord Markham (Conservative) on Wednesday, 12 April 2023 on behalf of the Department of Health and Social Care.

Tixagevimab/cilgavimab

Question: To ask His Majesty's Government, further to the Written Answer by Lord Markham on 6 March (HL5937), why the National Institute for Clinical Excellence (NICE) request for referral of 8 June is described as for “referral of Evusheld for treatment of COVID-19” but, as confirmed in a NICE freedom of information response, the request was for “referral of tixagevimab-cilgavimab for preventing COVID-19 [ID6136] on 8 June 2022”, causing delay to the possibility of a decision at a time when the preventative prophylaxis Evusheld was highly efficacious.

Answer: The request made by the National Institute for Health and Care Excellence (NICE) to the Department on 8 June 2022 was for the referral of Evusheld for the treatment of COVID-19 for inclusion into its multiple technology appraisal on therapeutics for COVID-19, not Evusheld for prevention. I understand from NICE that an error was made in its response to the freedom of information request, and that a correction will be issued accordingly. I apologise that this happened.

Secondary information

Type: Written question
Reference: HL6531
Session: 2022-23
Related items: Tixagevimab/cilgavimab
Monday, 6 March 2023
Written questions
House of Lords
Subjects: Freedom of information National Institute for Health and Care Excellence Testing Tixagevimab/cilgavimab
Link: View this Written question on www.parliament.uk